Detection of pre-neoplastic and neoplastic prostate disease by MADI profiling of urine

Amosy E. M'Koma, David L. Blum, Jeremy L. Norris, Tatsuki Koyama, David D Billheimer, Saundra Motley, Mayshan Ghiassi, Nika Ferdowsi, Indrani Bhowmick, Sam S. Chang, Jay H. Fowke, Richard M. Caprioli, Neil A. Bhowmick

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

The heterogeneous progression to the development of prostate cancer (PCa) has precluded effective early detection screens. Existing prostate cancer screening paradigms have relatively poor specificity for cancer relative to other prostate diseases, commonly benign prostatic hyperplasia (BPH). A method for discrimination of BPH, HGPIN, and PCa urine proteome was developed through testing 407 patient samples using matrix assisted laser desorption-mass spectrometry time of flight (MALDI-TOF). Urine samples were adsorbed to reverse phase resin, washed, and the eluant spotted directly for MALDI-TOF analysis of peptides. The processing resolved over 130 verifiable signals of a mass range of 1000-5000 m/z to suggest 71.2% specificity and 67.4% sensitivity in discriminating PCa vs. BPH. Comparing BPH and HGPIN resulted in 73.6% specificity and 69.2% sensitivity. Comparing PCa and HGPIN resulted in 80.8% specificity and 81.0% sensitivity. The high throughput, low-cost assay method developed is amenable for large patient numbers required for supporting biomarker identification.

Original languageEnglish (US)
Pages (from-to)829-834
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume353
Issue number3
DOIs
StatePublished - Feb 16 2007
Externally publishedYes

Fingerprint

Mass spectrometry
Prostatic Hyperplasia
Prostate
Desorption
Prostatic Neoplasms
Urine
Lasers
Biomarkers
Proteome
Assays
Screening
Resins
Sensitivity and Specificity
Throughput
Mass Spectrometry
Peptides
Testing
Processing
Costs
Early Detection of Cancer

Keywords

  • BPH
  • HGPIN
  • MALDI-TOF
  • Prostate cancer
  • PSA
  • Urine peptide profiling

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Detection of pre-neoplastic and neoplastic prostate disease by MADI profiling of urine. / M'Koma, Amosy E.; Blum, David L.; Norris, Jeremy L.; Koyama, Tatsuki; Billheimer, David D; Motley, Saundra; Ghiassi, Mayshan; Ferdowsi, Nika; Bhowmick, Indrani; Chang, Sam S.; Fowke, Jay H.; Caprioli, Richard M.; Bhowmick, Neil A.

In: Biochemical and Biophysical Research Communications, Vol. 353, No. 3, 16.02.2007, p. 829-834.

Research output: Contribution to journalArticle

M'Koma, AE, Blum, DL, Norris, JL, Koyama, T, Billheimer, DD, Motley, S, Ghiassi, M, Ferdowsi, N, Bhowmick, I, Chang, SS, Fowke, JH, Caprioli, RM & Bhowmick, NA 2007, 'Detection of pre-neoplastic and neoplastic prostate disease by MADI profiling of urine', Biochemical and Biophysical Research Communications, vol. 353, no. 3, pp. 829-834. https://doi.org/10.1016/j.bbrc.2006.12.111
M'Koma, Amosy E. ; Blum, David L. ; Norris, Jeremy L. ; Koyama, Tatsuki ; Billheimer, David D ; Motley, Saundra ; Ghiassi, Mayshan ; Ferdowsi, Nika ; Bhowmick, Indrani ; Chang, Sam S. ; Fowke, Jay H. ; Caprioli, Richard M. ; Bhowmick, Neil A. / Detection of pre-neoplastic and neoplastic prostate disease by MADI profiling of urine. In: Biochemical and Biophysical Research Communications. 2007 ; Vol. 353, No. 3. pp. 829-834.
@article{ad8c629a2326478789ee9eb05606b151,
title = "Detection of pre-neoplastic and neoplastic prostate disease by MADI profiling of urine",
abstract = "The heterogeneous progression to the development of prostate cancer (PCa) has precluded effective early detection screens. Existing prostate cancer screening paradigms have relatively poor specificity for cancer relative to other prostate diseases, commonly benign prostatic hyperplasia (BPH). A method for discrimination of BPH, HGPIN, and PCa urine proteome was developed through testing 407 patient samples using matrix assisted laser desorption-mass spectrometry time of flight (MALDI-TOF). Urine samples were adsorbed to reverse phase resin, washed, and the eluant spotted directly for MALDI-TOF analysis of peptides. The processing resolved over 130 verifiable signals of a mass range of 1000-5000 m/z to suggest 71.2{\%} specificity and 67.4{\%} sensitivity in discriminating PCa vs. BPH. Comparing BPH and HGPIN resulted in 73.6{\%} specificity and 69.2{\%} sensitivity. Comparing PCa and HGPIN resulted in 80.8{\%} specificity and 81.0{\%} sensitivity. The high throughput, low-cost assay method developed is amenable for large patient numbers required for supporting biomarker identification.",
keywords = "BPH, HGPIN, MALDI-TOF, Prostate cancer, PSA, Urine peptide profiling",
author = "M'Koma, {Amosy E.} and Blum, {David L.} and Norris, {Jeremy L.} and Tatsuki Koyama and Billheimer, {David D} and Saundra Motley and Mayshan Ghiassi and Nika Ferdowsi and Indrani Bhowmick and Chang, {Sam S.} and Fowke, {Jay H.} and Caprioli, {Richard M.} and Bhowmick, {Neil A.}",
year = "2007",
month = "2",
day = "16",
doi = "10.1016/j.bbrc.2006.12.111",
language = "English (US)",
volume = "353",
pages = "829--834",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Detection of pre-neoplastic and neoplastic prostate disease by MADI profiling of urine

AU - M'Koma, Amosy E.

AU - Blum, David L.

AU - Norris, Jeremy L.

AU - Koyama, Tatsuki

AU - Billheimer, David D

AU - Motley, Saundra

AU - Ghiassi, Mayshan

AU - Ferdowsi, Nika

AU - Bhowmick, Indrani

AU - Chang, Sam S.

AU - Fowke, Jay H.

AU - Caprioli, Richard M.

AU - Bhowmick, Neil A.

PY - 2007/2/16

Y1 - 2007/2/16

N2 - The heterogeneous progression to the development of prostate cancer (PCa) has precluded effective early detection screens. Existing prostate cancer screening paradigms have relatively poor specificity for cancer relative to other prostate diseases, commonly benign prostatic hyperplasia (BPH). A method for discrimination of BPH, HGPIN, and PCa urine proteome was developed through testing 407 patient samples using matrix assisted laser desorption-mass spectrometry time of flight (MALDI-TOF). Urine samples were adsorbed to reverse phase resin, washed, and the eluant spotted directly for MALDI-TOF analysis of peptides. The processing resolved over 130 verifiable signals of a mass range of 1000-5000 m/z to suggest 71.2% specificity and 67.4% sensitivity in discriminating PCa vs. BPH. Comparing BPH and HGPIN resulted in 73.6% specificity and 69.2% sensitivity. Comparing PCa and HGPIN resulted in 80.8% specificity and 81.0% sensitivity. The high throughput, low-cost assay method developed is amenable for large patient numbers required for supporting biomarker identification.

AB - The heterogeneous progression to the development of prostate cancer (PCa) has precluded effective early detection screens. Existing prostate cancer screening paradigms have relatively poor specificity for cancer relative to other prostate diseases, commonly benign prostatic hyperplasia (BPH). A method for discrimination of BPH, HGPIN, and PCa urine proteome was developed through testing 407 patient samples using matrix assisted laser desorption-mass spectrometry time of flight (MALDI-TOF). Urine samples were adsorbed to reverse phase resin, washed, and the eluant spotted directly for MALDI-TOF analysis of peptides. The processing resolved over 130 verifiable signals of a mass range of 1000-5000 m/z to suggest 71.2% specificity and 67.4% sensitivity in discriminating PCa vs. BPH. Comparing BPH and HGPIN resulted in 73.6% specificity and 69.2% sensitivity. Comparing PCa and HGPIN resulted in 80.8% specificity and 81.0% sensitivity. The high throughput, low-cost assay method developed is amenable for large patient numbers required for supporting biomarker identification.

KW - BPH

KW - HGPIN

KW - MALDI-TOF

KW - Prostate cancer

KW - PSA

KW - Urine peptide profiling

UR - http://www.scopus.com/inward/record.url?scp=33846027431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846027431&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2006.12.111

DO - 10.1016/j.bbrc.2006.12.111

M3 - Article

C2 - 17194448

AN - SCOPUS:33846027431

VL - 353

SP - 829

EP - 834

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -